JENSINE CAUDILL: Open Payments
NPI 1114681525 · OCOEE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,038 in 86 payments from 16 companies in 2025. Trend: 2023 $264 · 2024 $690 · 2025 $3,038
Food & beverage: $3,038
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $671 |
| Madrigal Pharmaceuticals | 6 | $386 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $348 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $247 |
| Ardelyx, Inc. | 7 | $214 |
| Phathom Pharmaceuticals, Inc. | 5 | $200 |
| ABBVIE INC. | 15 | $194 |
| Braintree Laboratories, Inc. | 3 | $157 |
| QOL Medical, LLC | 4 | $142 |
| GENZYME CORPORATION | 3 | $136 |
Products named: TREMFYA, REZDIFFRA, ENTYVIO, XIFAXAN, IBSRELA, VOQUEZNA, DUPIXENT, SUTAB.
Industry payments across FL — which companies pay providers there.
